Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

[1]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[2]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[3]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[5]  K. Alitalo,et al.  Signaling angiogenesis and lymphangiogenesis. , 1998, Current opinion in cell biology.

[6]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[7]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[8]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[9]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[10]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[11]  F. Rilke,et al.  DISTINCT mdm2/p53 EXPRESSION PATTERNS IN LIPOSARCOMA SUBGROUPS: IMPLICATIONS FOR DIFFERENT PATHOGENETIC MECHANISMS , 1997, The Journal of pathology.

[12]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[13]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[14]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[15]  Itzhak D. Goldberg,et al.  Regulation of Angiogenesis , 1996, Experientia Supplementum.

[16]  E. Abel.  Clinical applications of research on angiogenesis , 1996 .

[17]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[18]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M. Borrello,et al.  Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells , 1996, Genes, chromosomes & cancer.

[20]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[21]  G. Viglietto,et al.  Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. , 1995, Oncogene.

[22]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[23]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Borrello,et al.  Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. , 1995, Experimental cell research.

[25]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[26]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[27]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[28]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[29]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[30]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[31]  H. Schnürch,et al.  Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. , 1993, Development.

[32]  Johannes Gerdes,et al.  Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections , 1993, The Journal of pathology.

[33]  A. Iwama,et al.  Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. , 1993, Biochemical and biophysical research communications.

[34]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[36]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[37]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[38]  L. Liotta,et al.  Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.

[39]  Sharpe Rj,et al.  Growth Inhibition of Murine Melanoma and Human Colon Carcinoma by Recombinant Human Platelet Factor 4 , 1990 .

[40]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[41]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[42]  G. Tuszynski,et al.  The role of thrombospondin-1 in tumor progression and angiogenesis. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[43]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.

[44]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[45]  M. Klagsbrun,et al.  Regulators of angiogenesis. , 1991, Annual review of physiology.

[46]  H. Byers,et al.  Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. , 1990, Journal of the National Cancer Institute.

[47]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.